IL279186A - Use of 5-[[4-[2-[5-acetylpyridin-2-yl]ethoxy]benzyl]-1, 3-thiazolidine-2, 4-dione and their salts - Google Patents

Use of 5-[[4-[2-[5-acetylpyridin-2-yl]ethoxy]benzyl]-1, 3-thiazolidine-2, 4-dione and their salts

Info

Publication number
IL279186A
IL279186A IL279186A IL27918620A IL279186A IL 279186 A IL279186 A IL 279186A IL 279186 A IL279186 A IL 279186A IL 27918620 A IL27918620 A IL 27918620A IL 279186 A IL279186 A IL 279186A
Authority
IL
Israel
Prior art keywords
acetylpyridin
thiazolidine
dione
ethoxy
benzyl
Prior art date
Application number
IL279186A
Other languages
English (en)
Hebrew (he)
Inventor
Collazo Ana Maria Garcia
Pedemonte Marc Martinell
Lalanza Maria Pilar Pizcueta
Lopez Estefania Traver
De La Cruz Moreno Maria Angeles Perez
Original Assignee
Minoryx Therapeutics S L
Collazo Ana Maria Garcia
Pedemonte Marc Martinell
Lalanza Maria Pilar Pizcueta
Lopez Estefania Traver
De La Cruz Moreno Maria Angeles Perez
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Minoryx Therapeutics S L, Collazo Ana Maria Garcia, Pedemonte Marc Martinell, Lalanza Maria Pilar Pizcueta, Lopez Estefania Traver, De La Cruz Moreno Maria Angeles Perez filed Critical Minoryx Therapeutics S L
Publication of IL279186A publication Critical patent/IL279186A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL279186A 2018-06-06 2020-12-03 Use of 5-[[4-[2-[5-acetylpyridin-2-yl]ethoxy]benzyl]-1, 3-thiazolidine-2, 4-dione and their salts IL279186A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP18382402 2018-06-06
PCT/IB2019/054744 WO2019234690A1 (en) 2018-06-06 2019-06-06 Use of 5-[[4-[2-[5-acetylpyridin-2-yl]ethoxy]benzyl]-1,3-thiazolidine-2,4-dione and its salts

Publications (1)

Publication Number Publication Date
IL279186A true IL279186A (en) 2021-01-31

Family

ID=62716011

Family Applications (1)

Application Number Title Priority Date Filing Date
IL279186A IL279186A (en) 2018-06-06 2020-12-03 Use of 5-[[4-[2-[5-acetylpyridin-2-yl]ethoxy]benzyl]-1, 3-thiazolidine-2, 4-dione and their salts

Country Status (14)

Country Link
US (2) US20210228558A1 (enExample)
EP (1) EP3801517A1 (enExample)
JP (1) JP7510170B2 (enExample)
KR (1) KR20210031867A (enExample)
CN (1) CN112823004A (enExample)
AU (1) AU2019283650A1 (enExample)
BR (1) BR112020024939A2 (enExample)
CA (1) CA3102584A1 (enExample)
CL (1) CL2020003163A1 (enExample)
EA (1) EA202092954A1 (enExample)
IL (1) IL279186A (enExample)
MX (1) MX2020013182A (enExample)
SG (1) SG11202012095XA (enExample)
WO (1) WO2019234690A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130158077A1 (en) 2011-12-19 2013-06-20 Ares Trading S.A. Pharmaceutical compositions
MX2020013181A (es) 2018-06-06 2021-02-26 Minoryx Therapeutics S L Metodo para administrar una cantidad terapeuticamente efectiva de 5-[[4-[2-[5-(1-hidroxietil)piridin-2-il]etoxi]fenil]metil]-1,3-th iazolidin-2,4-diona.
HUE071482T2 (hu) 2018-06-06 2025-08-28 Minoryx Therapeutics S L (5-[[4-[2-[5-(1-Hidroxietil)piridin-2-il]etoxi]-fenil]metil]-1,3-tiazolidin-2,4- dion és sói mitokondriális betegségek kezelésében vagy megelõzésében történõ alkalmazásra
CN116390725A (zh) * 2020-04-30 2023-07-04 米尼奥尔克斯治疗有限公司 用于治疗肺部炎症和间质性肺病的羟基吡格列酮
WO2022243435A1 (en) * 2021-05-19 2022-11-24 Abliva Ab Kl1333 for use in medicine
WO2024231881A2 (en) * 2023-05-09 2024-11-14 Minoryx Therapeutics S.L. Polymorphic forms and formulations of leriglitazone

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3579049B2 (ja) 1992-04-30 2004-10-20 インスティチュート・パスツール Ｍｙｃｏｂａｃｔｅｒｉｕｍ ｔｕｂｅｒｃｕｌｏｓｉｓにおける抗生物質耐性の迅速検出法
GB0030845D0 (en) * 2000-12-18 2001-01-31 Smithkline Beecham Plc Novel treatment
GB0510469D0 (en) * 2005-05-23 2005-06-29 Leuven K U Res & Dev Insulin sensitization to slow down pubertal tempo and to augment pubertal growth
AU2012203941A1 (en) * 2006-06-27 2012-07-26 Sandoz Ag New method for salt preparation
EP2436381A1 (en) * 2006-06-27 2012-04-04 Sandoz AG Crystallization of hydrohalides of pharmaceutical compounds
WO2013040419A1 (en) * 2011-09-14 2013-03-21 The Trustees Of Columbia University In The City Of New York Compositions and methods for treating hyperprolinemia-associated mental disorders
CA2941562C (en) 2013-03-14 2021-09-21 Deuterx, Llc Deuterium-enriched 2,4-thiazolidinediones and methods of treatment
NZ725492A (en) 2014-04-02 2023-06-30 Minoryx Therapeutics S L 2,4-thiazolidinedione derivatives in the treatment of central nervous system disorders
WO2017083739A1 (en) * 2015-11-13 2017-05-18 The Trustees Of Columbia University In The City Of New York A method for predicting a subject's response to valproic acid therapy
CN110198945B (zh) 2016-12-23 2023-06-27 米尼奥尔克斯治疗有限公司 用于制备噻唑烷二酮化合物及其盐的方法

Also Published As

Publication number Publication date
CA3102584A1 (en) 2019-12-12
MX2020013182A (es) 2021-02-26
EA202092954A1 (ru) 2021-04-08
JP2021527061A (ja) 2021-10-11
SG11202012095XA (en) 2021-01-28
WO2019234690A1 (en) 2019-12-12
CL2020003163A1 (es) 2021-07-02
BR112020024939A2 (pt) 2021-03-09
AU2019283650A1 (en) 2021-01-07
US20240091210A1 (en) 2024-03-21
CN112823004A (zh) 2021-05-18
JP7510170B2 (ja) 2024-07-03
KR20210031867A (ko) 2021-03-23
EP3801517A1 (en) 2021-04-14
US20210228558A1 (en) 2021-07-29

Similar Documents

Publication Publication Date Title
SG11202012095XA (en) Use of 5-[[4-[2-[5-acetylpyridin-2-yl]ethoxy]benzyl]-1,3-thiazolidine-2,4-dione and its salts
FI3511319T3 (fi) Lysiinispesifisen demetylaasi-1:n inhibiittoreita
HUE059604T2 (hu) Eljárás 5-[[4-[2-[5-(1-hidroxietil)-2-piridinil]etoxi]fenil]metil]-2,4-tiazolidindion és sói elõállítására
IL265298B (en) History of 5-[2-(pyridin-2-ylamino)-3,1-thiazol-5-yl]-3,2,dihydro-1 h -isoindol-1-one and their use as dual inhibitors of phosphatidylinositol 3-kinase delta and gamma
HUE054346T2 (hu) 5-[[4-[2-[5-(1-Hidroxietil)piridin-2-il]etoxi]fenil]metil]-1,3-tiazolidin-2,4-dion nem-alkoholos zsírmáj-betegség kezelésére
PT3801515T (pt) 5-[[4-[2-[5-(1-hidroxietil)piridin-2-il]etoxi]fenil]metil]-1,3-tiazolidina-2,4-diona e seus sais para uso no tratamento de doenças mitocondriais
SI3873884T1 (sl) 3-(kinolin-8-il)-1,4-dihidropirido[3,4-d]pirimidin-2,4-dionski derivati kot zaviralci integrina alfa4beta7 za zdravljenje vnetnih bolezni
CL2015000332A1 (es) Forma cristalina a y racemato cristalino de 1-(5'-(5-(3,5-dicloro-4-fluorofenil)-5-(trifluorometil)-4,5-dihidroisoxazol-3-il)-3'h-espiro[azetidin-3,1'-isobenzofuran]-1-il)-2-(metilsulfonil)etanona; procedimiento de preparacion de la forma cristalina a; composicion que la comprende; y su uso para el tratamiento de una infeccion o infestacion parasitaria.
CL2010001636A1 (es) (r,z)-5-(2-(3-aminopiperidin-1-il)-3-isopropoxibencilideno)tiazolidin-2,4-diona, (r,z)-5-(2-(3-aminopiperidin-1-il)bifenil-3-ilmetilen)tiazolidin-2,4-diona, o una sal de los mismos; composicion farmaceutica; uso para el tratamiento del cancer y para la inhibicion de quinasa pim.
IL279183A (en) Method for administering a therapeutically effective amount of 5-[[4-[2-[5-(1-hydroxyethyl)pyridin-2-yl]ethoxy]phenyl]methyl]-1, 3-thiazolidine-2, 4-dione
EP2602258B8 (en) N-[5-(Aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-N-methyl-2-[4-(2-pyridinyl)phenyl]acetamide mesylate monohydrate
LT3544976T (lt) N-[5-(aminosulfonil)-4-metil-1,3-tiazol-2-il]-n-metil-2-[4-(2-piridinil)-fenil]-acetamido laisvos bazės hemihidratas, jo gamybos būdai ir panaudojimai
MX2022013021A (es) Leriglitazona para tratar inflamacion pulmonar y enfermedad pulmonar intersticial.
WO2012036919A3 (en) Combination of braf and vegf inhibitors
HK40049678A (en) Use of 5-[[4-[2-[5-acetylpyridin-2-yl]ethoxy]benzyl]-1,3-thiazolidine-2,4-dione and its salts
HK40050840A (en) Method of administering a therapeutically effective amount of 5-[[4-[2-[5-(1-hydroxyethyl)pyridin-2-yl]ethoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione
SI3019497T1 (sl) Nova sol 3-((3-((4-(4-morfolinilmetil)-1h-pirol-2-il)metilen)-2-okso- 2,3-dihidro-1h-indol-5-il)metil)-1,3-tiazolidin-2,4-diona, njen sestavek in formulacije, ki jo vsebujejo
IL257232A (en) Linkage between 3-[(3-{[4-(4-morpholinylmethyl)-h1-pyrrol-2-yl)methylene}-2-oxo-3,2-dihydro-h1-indol-5-yl)methyl]- 3,1-thiazolidine-4,2-dione and egfr tyrosine kinase inhibitor
PH12017500123B1 (en) Crystal of azole benzene derivative
TH1601000138A (th) เกลือชนิดใหม่ของ 3-[(3-{[4-(4-มอร์โฟลินิลเมทธิล)-1h-ไพร์รอล-2-อิล]เมทธิลลีน}-2-ออกโซ-2,3-ไดไฮโดร-1h-อินดอล-5-อิล)เมทธิล]-1,3-ไธอะโซลิดีน-2,4-ไดโอน การเตรียมของมันและสูตรผสมที่มีมันประกอบอยู่
PL385697A1 (pl) Sól 5-[[4-[2-(metylo-2-pirydynyloamino)etoksy]fenylo]metylo]-2, 4-tiazolidynodionu z kwasem 1, 5-naftalenodisulfonowym i sposób jej wytwarzania
BR112016022974A2 (pt) derivados de 2,4-tiazolidinadiona no tratamento de distúrbios do sistema nervoso central